Johnson & Johnson's single-shot COVID-19 vaccine showing 'strong, persistent activity against Delta variant'
US pharma major Johnson & Johnson, on Friday announced that its single-dose COVID-19 vaccine has shown effective results to counter the deadly Delta variant. The company released data that demonstrated that its single-shot COVID-19 vaccine has generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.
The development comes shortly after Johnson and Johnson announced that a bridging clinical study of its single-dose Janssen COVID-19 vaccine was no longer required in India.
Johnson and Johnson vaccine may be available in India later this month
Earlier this week, the company had said that it was in talks with the Indian government to speed up the delivery of its single-shot vaccine. According to reports, the single-shot vaccine is expected to be available in India later this month.
According to the World Health organisation (WHO), Johnson and Johnson's vaccine efficiency was 66.3 per cent for mild to moderate severity of COVID-19 and was 76.3 per cent for severe infection. According to reports, the vaccine provides 100 per cent protection from hospitalisation 28 days after taking the jab.